Guest Speaker

Eufrosina Young, MD
Platform Trial Site Investigator
SUNY Upstate, Syracuse NY
ALS Clinic at SUNY Upstate

- MD: Dr. Eufrosina Young
- RN’s: Jeff Collins, Dawn Dailey
- Clinic Coordinator: Stephanie Lessun, LMSW
- Social Worker: Samantha Ueberroth, LMSW
- Spiritual Care: Father Eric Malcom
- ALSA Care Services Coordinator: Rabecca Coulter, LMSW
- Additional Providers: OT, PT, SLP, RD, RRTs, Research Coordinators

- For clinic coordinator inquiries, please reach out to lessuns@upstate.edu, 315-464-5899.
SUNY Upstate Healey Team

• Site Investigator:
  – Eufrosina Young (YoungEu@upstate.edu)

• Sub-Investigator:
  – Jenny Meyer (MeyerJe@upstate.edu)

• Primary Research Coordinator:
  – Lena Deb (DebL@upstate.edu)

• Secondary Research Coordinator:
  – Marielle DeMasi (DemasiM@upstate.edu)
The HEALEY ALS Platform Trial is a Perpetual Adaptive Trial

3:1 Randomization within each Regimen

- **Regimen A**
  - (n=160 for each regimen)
  - Placebo

- **Regimen B**
  - Placebo

- **Regimen C**
  - Placebo

- **Regimen D**
  - Placebo

- **Regimen E**
  - Placebo

**Zilucoplan**
- Placebo

**Verdiperstat**
- Placebo

**CNM-Au8**
- Placebo

**Pridopidine**
- Placebo

**Trehalose**
- Placebo

**Shared Placebo**
Enrollment Updates (as of July 14, 2022)

- 90 individuals have signed informed consent
- 63 individuals have been randomized within Regimen E

Thank You

This breakthrough trial would not be possible without your participation.

Your partnership in research is what keeps us filled with passion, dedication, and the commitment to uncover new promising treatments for ALS.

Every research participant, whether on the active drug or placebo, plays a critical role in making the hope of finding a cure for ALS a reality.
39 Sites Currently Activated for Regimen E

(as of 7/14/22)

Sites in blue participated in previous regimens. Sites in green (underlined to the side) are new additions to the Platform Trial!

Lehigh Valley Health Network
Mass General Hospital
University of Kansas
University of Maryland
California Pacific Medical Center
Northwestern University
Virginia Commonwealth University
University of Nebraska
Washington University
Wake Forest University
Hospital for Special Care
Saint Alphonsus Regional
University of Massachusetts
Duke University
Barrow Neurological Institute
Georgetown University
Texas Neurology
Beth Israel Deaconess Medical Center
SUNY Upstate
Spectrum Health
Henry Ford Hospital
Essentia Health
University of Southern California
University of South Florida
University of Colorado
Providence Brain and Spine
University of Minnesota
Loma Linda University
University of Iowa
Swedish Medical Center
Ohio State University
University of Cincinnati
Thomas Jefferson University
UC San Francisco
Mayo Rochester
University of Washington
Vanderbilt University
UPMC
Indiana University

https://bit.ly/3g2NZr5
Indiana University Now Active for Regimen E
Contact: Sandy Guingrich
Email: sguingri@iu.edu (preferred)
Phone: 317-963-7382

Latest News

Investigational drug ABBV-CLS-7262 initiates design phase for entry into the HEALEY ALS Platform Trial

Patient Navigation
Central resource for people living with ALS

Phone: 833-425-8257 (HALT ALS)
E-mail: healeyalsplatform@mgh.harvard.edu

Weekly webinar registration:  
https://bit.ly/3r6Nd2L

ALS Link sign-up:  
https://bit.ly/3o2Ds3m

Upcoming Guest Speakers:
*TBD* July 28th- Lori Chibnik, PhD, MPH (Biostatistics Discussion about Placebos)
Genes in ALS

Register Below:


This webinar will provide an approachable overview of the major genes involved in ALS: what those genes are, how they lead to ALS, and what ideas they are giving scientists for treating all forms of ALS. There will be time at the end of the presentation for questions.